Global Markets Direct’s, 'Vaginitis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Vaginitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Vaginitis. Vaginitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Vaginitis. - A review of the Vaginitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Vaginitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Vaginitis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Vaginitis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table Of Contents
Vaginitis - Pipeline Review, H1 2013 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Vaginitis Overview 6 Therapeutics Development 7 An Overview of Pipeline Products for Vaginitis 7 Vaginitis Therapeutics under Development by Companies 9 Vaginitis Therapeutics under Investigation by Universities/Institutes 10 Late Stage Products 11 Comparative Analysis 11 Early Clinical Stage Products 12 Comparative Analysis 12 Discovery and Pre-Clinical Stage Products 13 Comparative Analysis 13 Vaginitis Therapeutics - Products under Development by Companies 14 Vaginitis Therapeutics - Products under Investigation by Universities/Institutes 15 Companies Involved in Vaginitis Therapeutics Development 16 Centaur Pharmaceuticals Pvt. Ltd. 16 BioDiem Ltd 17 NanoBio Corporation 18 Lee's Pharmaceutical Holdings Limited 19 Vaginitis - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Combination Products 21 Assessment by Route of Administration 22 Assessment by Molecule Type 24 Drug Profiles 26 Drug For Vaginitis - Drug Profile 26 Product Description 26 Mechanism of Action 26 RandD Progress 26 (miconazole nitrate + neomycin sulphate + tinidazole) - Drug Profile 27 Product Description 27 Mechanism of Action 27 RandD Progress 27 BDM-I - Drug Profile 28 Product Description 28 Mechanism of Action 28 RandD Progress 28 ZK-004 - Drug Profile 29 Product Description 29 Mechanism of Action 29 RandD Progress 29 Drug For Candiasis - Drug Profile 30 Product Description 30 Mechanism of Action 30 RandD Progress 30 TOL-463 - Drug Profile 31 Product Description 31 Mechanism of Action 31 RandD Progress 31 Vaginitis Therapeutics - Drug Profile Updates 32 Vaginitis Therapeutics - Dormant Products 34 Vaginitis - Product Development Milestones 35 Featured News and Press Releases 35 Nov 21, 2012: BioDiem Files Japanese Patent Application For Antimicrobial Compound BDM-I 35 Aug 08, 2012: BioDiem Receives European Patent For Antimicrobial Compound BDM-I 36 Appendix 37 Methodology 37 Coverage 37 Secondary Research 37 Primary Research 37 Expert Panel Validation 37 Contact Us 38 Disclaimer 38
List of Tables
Number of Products Under Development for Vaginitis, H1 2013 7 Products under Development for Vaginitis - Comparative Analysis, H1 2013 8 Number of Products under Development by Companies, H1 2013 9 Number of Products under Investigation by Universities/Institutes, H1 2013 10 Comparative Analysis by Late Stage Development, H1 2013 11 Comparative Analysis by Early Clinical Stage Development, H1 2013 12 Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 13 Products under Development by Companies, H1 2013 14 Products under Investigation by Universities/Institutes, H1 2013 15 Centaur Pharmaceuticals Pvt. Ltd., H1 2013 16 BioDiem Ltd, H1 2013 17 NanoBio Corporation, H1 2013 18 Lee's Pharmaceutical Holdings Limited, H1 2013 19 Assessment by Monotherapy Products, H1 2013 20 Assessment by Combination Products, H1 2013 21 Assessment by Stage and Route of Administration, H1 2013 23 Assessment by Stage and Molecule Type, H1 2013 25 Vaginitis Therapeutics - Drug Profile Updates 32 Vaginitis Therapeutics - Dormant Products 34
List of Figures
Number of Products under Development for Vaginitis, H1 2013 7 Products under Development for Vaginitis - Comparative Analysis, H1 2013 8 Products under Development by Companies, H1 2013 9 Products under Investigation by Universities/Institutes, H1 2013 10 Late Stage Products, H1 2013 11 Early Clinical Stage Products, H1 2013 12 Discovery and Pre-Clinical Stage Products, H1 2013 13 Assessment by Monotherapy Products, H1 2013 20 Assessment by Combination Products, H1 2013 21 Assessment by Route of Administration, H1 2013 22 Assessment by Stage and Route of Administration, H1 2013 23 Assessment by Molecule Type, H1 2013 24 Assessment by Stage and Molecule Type, H1 2013 25